• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导化疗或放化疗联合根治性食管切除术治疗 T4 期食管癌:一项前瞻性队列研究的结果。

Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study.

机构信息

Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.

出版信息

World J Surg. 2013 Sep;37(9):2180-8. doi: 10.1007/s00268-013-2074-x.

DOI:10.1007/s00268-013-2074-x
PMID:23649529
Abstract

BACKGROUND

We hypothesized that the survival rate of patients undergoing R0 esophagectomy after induction chemotherapy or chemoradiotherapy for unresectable T4 esophageal cancer (URT4) would be similar to that of patients undergoing esophagectomy for immediately resectable esophageal cancer with no unfavorable prognostic factors (RNU).

METHODS

Between April 2002 and June 2012, 87 of 283 patients with esophageal cancer who presented at the University Hospital of the Ryukyus were enrolled in this prospective cohort study. Tumors were classified as RNU and URT4 in 44 and 43 of the 87 patients, respectively. Outcomes of treatment for URT4 patients were compared with those of RNU patients.

RESULTS

The R0 resection rate (61 %) and in-hospital mortality rate (20 %) of URT4 patients were significantly poorer than those of RNU patients (98 and 2.3 %, respectively), although the morbidity rate was similar in the two groups (63 and 52 %, respectively). The 5-year survival rate (35 %) of URT4 patients was significantly poorer than that of RNU patients (67 %) in the intention-to-treat analysis. However, no significant difference was noted between the two survival curves for cases of R0 resection (5-year survival rate, 60 % vs. 69 %). Multivariate analysis revealed R status as the only significant independent prognostic factor for URT4 patients (P < 0.001; hazard ratio = 8.279).

CONCLUSIONS

Satisfactory survival rates can be achieved if R0 resection is performed after induction treatment in patients with T4 esophageal cancer, although secondary radical esophagectomy is associated with a higher risk of in-hospital mortality.

摘要

背景

我们假设,对于不可切除的 T4 期食管癌(URT4)患者,在接受诱导化疗或放化疗后行 R0 食管切除术的生存率与行根治性切除术的可立即切除食管癌患者(RNU)相似,且这些患者没有不利的预后因素。

方法

2002 年 4 月至 2012 年 6 月,在琉球大学医院就诊的 283 例食管癌患者中,有 87 例被纳入本前瞻性队列研究。44 例和 43 例患者的肿瘤分别被分类为 RNU 和 URT4。URT4 患者的治疗结果与 RNU 患者进行了比较。

结果

URT4 患者的 R0 切除率(61%)和住院死亡率(20%)明显差于 RNU 患者(分别为 98%和 2.3%),尽管两组的发病率相似(分别为 63%和 52%)。意向治疗分析显示,URT4 患者的 5 年生存率(35%)明显低于 RNU 患者(67%)。然而,对于 R0 切除的病例,两条生存曲线之间没有显著差异(5 年生存率,60%比 69%)。多变量分析显示,R 状态是 URT4 患者唯一的显著独立预后因素(P <0.001;风险比=8.279)。

结论

如果在诱导治疗后对 T4 期食管癌患者行 R0 切除术,可获得令人满意的生存率,尽管辅助根治性食管切除术与更高的住院死亡率相关。

相似文献

1
Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study.诱导化疗或放化疗联合根治性食管切除术治疗 T4 期食管癌:一项前瞻性队列研究的结果。
World J Surg. 2013 Sep;37(9):2180-8. doi: 10.1007/s00268-013-2074-x.
2
Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy.接受诱导化疗或放化疗的T4期食管癌患者行食管切除术后预测R0切除及长期生存的临床病理因素
Surg Today. 2015 Apr;45(4):479-86. doi: 10.1007/s00595-014-0980-7. Epub 2014 Jul 25.
3
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.诱导化疗改善了接受放化疗后手术的可切除食管癌患者的预后。
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033.
4
Prognostic Factors and Appropriate Lymph Node Dissection in Salvage Esophagectomy for Locally Advanced T4 Esophageal Cancer.局部晚期 T4 期食管癌挽救性食管切除术后的预后因素和合适的淋巴结清扫范围。
Ann Surg Oncol. 2019 Jan;26(1):209-216. doi: 10.1245/s10434-018-7074-5. Epub 2018 Nov 21.
5
Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.R0 切除术后局部食管癌患者新辅助放化疗前后的比较定量淋巴结评估。
J Gastrointest Surg. 2017 Sep;21(9):1377-1384. doi: 10.1007/s11605-017-3478-y. Epub 2017 Jun 29.
6
Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?食管鳞状细胞癌患者根治性放化疗后挽救性食管切除术:谁真正能从这种高风险手术中获益?
Ann Surg Oncol. 2015 Dec;22(13):4438-44. doi: 10.1245/s10434-015-4556-6. Epub 2015 Apr 11.
7
Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.新辅助放化疗后食管癌患者环周切缘的预后价值及其定义
Dis Esophagus. 2018 Feb 1;31(2). doi: 10.1093/dote/dox117.
8
Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.经胸食管癌切除术,行根治性纵隔和腹部淋巴结清扫及颈部食管胃吻合术治疗食管癌。
Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5. doi: 10.1016/s0003-4975(01)03203-9.
9
Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.新辅助治疗后开放与微创Ivor Lewis食管癌切除术的疗效
Ann Thorac Surg. 2016 Mar;101(3):1097-103. doi: 10.1016/j.athoracsur.2015.09.062. Epub 2015 Dec 1.
10
Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors.三联化疗后行根治性食管切除术治疗伴有不良预后因素的可切除食管癌的临床及肿瘤学疗效
Surg Today. 2014 Jul;44(7):1273-81. doi: 10.1007/s00595-013-0700-8. Epub 2013 Aug 21.

引用本文的文献

1
Outcomes of patients with clinical stage IV esophageal squamous cell carcinoma treated initially with definitive chemoradiotherapy: a single-institution observational study and literature review.初始接受根治性放化疗的临床IV期食管鳞状细胞癌患者的结局:一项单机构观察性研究及文献综述
Surg Today. 2025 Jul 4. doi: 10.1007/s00595-025-03087-x.
2
Conversion surgery for esophageal and esophagogastric junction cancer.食管和食管胃交界部癌的转化手术。
Int J Clin Oncol. 2024 Dec;29(12):1777-1784. doi: 10.1007/s10147-024-02639-4. Epub 2024 Oct 22.
3
Endobronchial Ultrasonography to Assess and Evaluate Tracheobronchial Tree Invasion in cT4b Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: Assessment of Resectability.

本文引用的文献

1
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation.根治性放化疗治疗食管癌患者的失败模式。
Cancer. 2012 May 15;118(10):2632-40. doi: 10.1002/cncr.26586. Epub 2011 Oct 5.
2
Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs.诱导三联化疗治疗侵犯邻近器官的食管癌的临床相关性。
J Surg Oncol. 2012 Sep 15;106(4):441-7. doi: 10.1002/jso.23081. Epub 2012 Feb 27.
3
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
经支气管超声检查评估和评价接受根治性放化疗的cT4b期食管癌患者气管支气管树侵犯情况:可切除性评估
Ann Surg Oncol. 2025 Jan;32(1):284-292. doi: 10.1245/s10434-024-15621-1. Epub 2024 Jul 6.
4
Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial.卡瑞利珠单抗联合化疗与同期放化疗治疗局部晚期不可切除食管鳞癌的转化治疗:一项两臂、开放标签、Ⅱ期临床试验方案。
BMJ Open. 2024 Feb 28;14(2):e075421. doi: 10.1136/bmjopen-2023-075421.
5
Role of surgery in T4N0-3M0 esophageal cancer.外科手术在 T4N0-3M0 期食管癌中的作用。
World J Surg Oncol. 2023 Nov 27;21(1):369. doi: 10.1186/s12957-023-03239-8.
6
Multimodal Treatment Strategies to Improve the Prognosis of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Narrative Review.改善局部晚期胸段食管鳞状细胞癌预后的多模式治疗策略:一项叙述性综述
Cancers (Basel). 2022 Dec 20;15(1):10. doi: 10.3390/cancers15010010.
7
Surgical strategies for treatment of clinical T4 esophageal cancer in Japan.日本临床T4期食管癌的手术治疗策略
Glob Health Med. 2021 Dec 31;3(6):371-377. doi: 10.35772/ghm.2020.01090.
8
Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy.挽救性机器人辅助微创食管癌切除术(RAMIE)治疗根治性放化疗后T4b期食管癌
Ann Surg Oncol. 2021 May;28(5):2730-2738. doi: 10.1245/s10434-020-09425-2. Epub 2020 Dec 19.
9
Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy.分析化放疗治疗 T4 期食管癌患者瘘的形成。
Esophagus. 2020 Jan;17(1):67-73. doi: 10.1007/s10388-019-00691-y. Epub 2019 Sep 10.
10
Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis.手术与 T4a 食管腺癌患者生存获益相关:一项全国性分析。
Ann Thorac Surg. 2019 Dec;108(6):1633-1639. doi: 10.1016/j.athoracsur.2019.05.091. Epub 2019 Jul 26.
一项比较术后顺铂联合氟尿嘧啶辅助化疗与术前化疗治疗局部晚期食管鳞状细胞癌(JCOG9907)的随机临床试验。
Ann Surg Oncol. 2012 Jan;19(1):68-74. doi: 10.1245/s10434-011-2049-9. Epub 2011 Aug 31.
4
Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.可切除食管鳞状细胞癌单纯手术与放化疗联合选择性手术的前瞻性比较。
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):348-56. doi: 10.1016/j.ijrobp.2009.02.086.
5
Treatment of thoracic esophageal carcinoma invading adjacent structures.侵犯相邻结构的胸段食管癌的治疗。
Cancer Sci. 2007 Jul;98(7):937-42. doi: 10.1111/j.1349-7006.2007.00479.x. Epub 2007 Apr 18.
6
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.与单纯放化疗相比,放化疗后手术治疗食管鳞癌:FFCD 9102研究
J Clin Oncol. 2007 Apr 1;25(10):1160-8. doi: 10.1200/JCO.2005.04.7118.
7
Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP).采用每日低剂量5-氟尿嘧啶和顺二氯二氨铂(CDDP)对局部晚期食管癌进行放化疗的长期结果。
Int J Clin Oncol. 2007 Feb;12(1):25-30. doi: 10.1007/s10147-006-0617-y. Epub 2007 Feb 25.
8
Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma.
Scand J Gastroenterol. 2005 Aug;40(8):886-92. doi: 10.1080/00365520510015601.
9
Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery.食管癌切除术:对于局部晚期T4期食管癌,放化疗后是否有必要进行?比较放化疗联合手术与单纯放化疗的前瞻性非随机试验。
World J Surg. 2005 Jan;29(1):25-30; discussion 30-1. doi: 10.1007/s00268-004-7590-2.
10
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).顺铂与5-氟尿嘧啶同步放疗用于晚期食管鳞状细胞癌的II期研究:日本食管癌肿瘤学组(JEOG)/日本临床肿瘤学会试验(JCOG9516)
Jpn J Clin Oncol. 2004 Oct;34(10):615-9. doi: 10.1093/jjco/hyh107.